

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- Abscess, 14t, 45-46
 clinical features/diagnosis, 45
 gas-containing, 14t, 28
 MRSA and, 25, 27
 pathogens, 45
 treatment, 11, 26, 45-46
- Acetic acid compresses, 72
- Acinetobacter baumannii*, 98, 99
- Acquired immunodeficiency syndrome. See *AIDS*.
- Actinomyces* spp, 73
- Acute bacterial skin and skin structure infections (ABSSSIs), 103, 105
- Acute paronychia, 14t, 177-178, 179-180
- Acyclovir, 122, 123, 124t-125t
 for VZV, 133-135, 134t
- Adenopathy
 inguinal, 119, 121
 regional, 59
- Aeromonas hydrophila*, 57, 68
- AIDS (acquired immunodeficiency syndrome)
 antiviral therapy, 139-140
 onychomycosis and, 169
- Alastrim, 143
- Alcohol-based products, 30
- Alcoholism, 55
- Allylamines, 163t, 181t
- Aluminum chloride, 70, 73
- American Academy of Dermatology, 155
- Amikacin, 72
- Aminoglycosides, 15, 15t, 68, 71
- Amoxicillin/clavulanate, 52, 57-58, 78, 82t, 84t
- Ampicillin/sulbactam, 78, 79, 82t, 84t
- Anaerobes, 16t, 29, 77, 82t
- Anesthesia, skin, 14t, 28, 78
- Animal bites, 28, 57-58, 78-79
 treatment, 78-79, 82t-83t
- Anogenital warts, 145-146, 146t, 147
 treatment, 147-149, 148t
- Anti-DNAase titers, 59
- Antibacterial soaps, 49, 52, 70
- Antibiograms, local, 52, 57
- Antibiotic therapies, 13-24, 15t, 16-17t. See also *specific agents and classes of agents*.
- amikacin, 72
- aminoglycosides, 15, 15t, 68, 71
- amoxicillin/clavulanate, 52, 57-58, 78, 82t, 84t
- ampicillin/sulbactam, 78, 79, 82t, 84t
- antibacterial soaps, 49, 52, 70
- azithromycin, 16, 52, 63
- aztreonam, 68, 107t
- bacitracin, 22t-24t, 63
- β -lactam drugs, 15-16, 28, 40-44
- carbapenems, 101
- cefaclor, 16t
- cefdinir, 16t, 18, 20, 40-44
- cefixime, 16t
- cefotaxime, 57, 72, 83t
- cefpodoxime, 16t
- cefprozil, 16t
- ceftaroline, 103-105
- ceftazidime, 72
- ceftibuten, 16t
- ceftriaxone, 57, 83t, 96t
- cefuroxime, 83t
- cephalexin, 16t, 19, 83t, 85t
- cephalosporins, 16t
- cephalothin, 22t-24t
- chlorhexidine wash, 30, 49
- ciprofloxacin, 83t, 85t
- clarithromycin, 52, 63
- clindamycin, 15-16, 22t-24t, 83t, 85t
 for complicated infections, 82t-85t, 86-105, 88t-89t
 concentration-dependent vs time-dependent, 13-16, 15t
- daptomycin, 89t, 90-94
- dicloxacillin, 30, 49, 52, 57, 67, 82t
- dosing strategies, 13-16
- doxycycline, 57, 79, 82t, 84t
- empiric, 29, 39, 40-44
- erythromycin, 15-16, 22t-24t
- fluoroquinolones, 17t, 83t, 85t, 87

Antibiotic therapies (*continued*)

fusidic acid, 18t, 22t-24t, 31
gentamicin, 22t-24t, 68, 87
IV, 57, 78
ketolides, 15t
lauric acid monoester ointments, 29
levofloxacin, 96t
lincosamides, 17t
linezolid, 87-90, 88t
macrolides, 17t
MIC values, 13, 18, 21t-24t
mupirocin, 18t, 22t-24t
nafcillin, 86
neomycin, 22t-24t, 63
oral, 16t-17t, 21t
parenteral, 41-42, 44, 57
penicillins, 16t-17t, 40-44
persistent effects (time-dependent), 15-16
pharmacokinetics of, 17-18, 19-20
piperacillin, 68, 82t
piperacillin/tazobactam, 58, 96t
PK profiles, 17-18, 19-20
pleuromutilins, 32
potency and susceptibility, 21t
potency of, 13-16
quinolones, 71
quinupristin-dalfopristin, 89t, 99-101
retapamulin, 32-33
sulfa drugs, 26-27
telavancin, 101-103
tetracyclines, 17t
tigecycline, 89t, 94-99
TMP/SMX, 17t, 40-44
topical agents, 18t, 29-33
vancomycin, 86-87, 88t
Antidepressants, tricyclic, 135
Antifungal agents. See also *specific agents*.
allylamines, 163t, 181t
benzylamines, 163t, 181t
butenafine, 163t, 181t
ciclopirox olamine, 163t, 181t
clotrimazole, 162t, 180t, 183t

Antifungal agents (*continued*)

duration of therapy, 160-161, 166, 172
econazole, 72, 160, 162t, 180t
fluconazole, 155, 156t, 187t, 188
griseofulvin, 155, 156t, 160, 166
imidazoles, 162t-163t, 165-166, 180t-181t
itraconazole, 156t, 171t, 187t
ketoconazole, 162t, 180t
miconazole, 162t, 180t
naftifine, 163t
nystatin, 179, 182, 183t
oxiconazole, 162t, 180t
selenium sulfide, 155, 186-188, 187t
sertaconazole, 162t, 180t
sulconazole, 163t, 181t
terbinafine, 156t, 163t, 171t, 181t
tolnaftate, 70, 186
topical, 159-160, 162t-163t, 172-174, 180t-181t, 187t
Antihistamines, 133
Antipyretics, 133
Antiretroviral therapy, 139t, 140
Antistreptolysin (ASO), 59
Antiviral agents. See also *specific agents*.
acyclovir, 122, 123, 124t-125t
antiretroviral therapy, 139t, 140
cidofovir, 115-116, 125t, 139t, 140, 148t
famciclovir, 122-123, 124t-125t
5-fluorouracil, 148t
foscarnet, 125t
imiquimod, 116, 139-140, 148t
penciclovir, 124t
podophyllin, 139, 148t
podophyllotoxin, 139, 148t
topical agents, 115-116
topical vs systemic, 115-116
valacyclovir, 122, 124t-125t
Arbekacin, 86
Aspergillus spp, 68
Athlete's foot (tinea pedis), 164-166, 164, 165
Atopic dermatitis, infected, 14t
Azithromycin, 16, 52, 63
Aztreonam, 68, 107t

Bacitracin, 22t-24t, 63
 Bacteremia, 65, 90, 92-93
 Bacterial infections, 13-114
 abscess, 45-46
 antibiotic therapies for, 13-24
 cellulitis, 55-58
 complicated infections, 77-114
 ecthyma and ecthyma gangrenosum, 65-68
 erysipelas, 59-60
 erythrasma, 69-70
 folliculitis and hot-tub folliculitis, 47-50
 furuncles/carbuncles, 51-53
 impetigo, 61-64
 MRSA, 25-38
 perianal streptococcal disease, 75-76
 pitted keratolysis, 73-74
 toe-web infection, 71-72
 topical therapies for, 18t
 treatment algorithms, 39, 40-44
Bacteroides tectum, 78
 Balanitis, 119
 Bartonella, 198
 Benzoic acid, 70
 Benzoyl peroxide, 70, 74
 Benzyl benzoate, 205
 Benzylamines, 163t, 181t
 β -Hemolytic streptococci, 59, 62, 65, 75
 β -Lactam drugs, 15-16, 28, 40-44
 Biofeedback, 135
 Biologic warfare, 115
 Bites
 animal, 28, 57-58, 78-79, 82t-83t
 bite reactions, lice, 193, 198
 human, 28, 79-81, 84t-85t
 pathogens in, 78, 79
 Blistering distal dactylitis, 14t
 Bockhart's impetigo, 47
 Body lice, 189. See also *Lice*.
 Boils. See *Furuncles/carbuncles*.
 Bullous impetigo, 61
 Burns, tigecycline and, 99
 Butenafine, 160, 163t, 181t, 186, 187t
 C-reactive protein, 28
 CA-MRSA (community-acquired MRSA), 25-38.
 See also *MRSA*.
 abscess with, 25, 27
 groups at risk, 25, 26t
 treatment, 25, 26-29
 Calamine lotion, 133
Candida and candidiasis, 177-184
 candidal intertrigo, 177, 178
 clinical features/diagnosis, 152, 177-179, 178
 ecthyma gangrenosum and, 68
 energy source, 151
 perianal streptococcal disease and, 75
 treatment, 179-182, 180t-181t, 183t
 Cantharidin, 139
Capnocytophaga canimorsus, 57, 78
 Capsaicin, 135
 Carbapenems, 15t, 101
 treatment uses, 28, 78, 82t, 84t
 Carbuncles. See *Furuncles/Carbuncles*.
 Castellani's paint, 72
 Cat bites, 57
 CDC (Centers for Disease Control and Prevention), 143
 Cefaclor, 16t
 Cefazolin, 57, 83t, 85t
 Cefdinir, 16t, 40-44
 PK profile, 18, 20
 Cefditoren, 16t
 Cefixime, 16t
 Cefotaxime, 57, 72, 83t
 Cefoxitin, 78, 83t
 Cefpodoxime, 16t
 Cefprozil, 16t
 Ceftaroline, 103-105
 activity spectrum, 103
 approved uses, 103
 clinical cure rates, 104-105, 106t
 MIC values, 103, 105, 106t
 pharmacokinetics, 104
 phase 3 trials, 104-105, 106t
 safety and tolerability, 105
 Ceftaroline fosamil, 103, 104

Ceftazidime, 72
 Ceftibuten, 16t
 Ceftriaxone, 57, 83t, 96t
 Cefuroxime, 83t
 Cellulitis, 14t, 55-58
 clinical features/diagnosis, 54, 55-56
 pathogens, 57
 predisposing conditions, 55, 57, 58
 toe-web infection and, 71
 treatment, 57-58
 Centers for Disease Control and Prevention (CDC), 143
 Cephalixin, 16t, 18, 19, 83t, 85t
 Cephalosporins, 15-16, 15t, 16t
 broad spectrum. See *Ceftaroline*.
 extended-spectrum third-generation, 16t
 first-generation, 16t, 83t
 PK profiles, 17-18, 19-20
 second-generation, 16t, 83t
 third-generation, 16t, 83t
 treatment uses, 40-44, 49, 52, 57, 63, 65, 68, 71, 83t, 85t
 for MRSA, 28, 30
 Cephalothin, 22t-24t
 Cerebrospinal fluid (CSF), 121-122
 Chancre, 122t
 Chickenpox (primary varicella), 127-128, 128-129, 142t.
 See also *Varicella zoster*.
Chlamydia, 199
 Chlorhexidine wash, 30, 49
 Ciclopirox olamine, 160, 172-174, 179, 182, 186, 187t
 formulations and dosing, 163t, 181t
 Cidofovir, 115-116, 125t, 139t, 140, 148t, 149
 Ciprofloxacin, 25, 58, 72, 83t, 85t
 Clarithromycin, 52, 63
 Clavulanate. See *Amoxicillin/clavulanate*.
 Clindamycin, 15-16, 22t-24t
 treatment uses, 52, 57, 69, 73, 83t, 85t
 for MRSA, 25, 27, 28, 30
 Clinical features
 of bacterial infections
 abscess, 45
 cellulitis, 54, 55-56
 ecthyma and ecthyma gangrenosum, 65, 66, 67
 Clinical features, of bacterial infections (*continued*)
 erysipelas, 59, 60
 erythrasma, 69, 70
 folliculitis and hot-tub folliculitis, 47-48
 furuncles/carbuncles, 51, 52
 impetigo, 61, 62
 MRSA, 25-28
 perianal streptococcal disease, 75, 76
 pitted keratolysis, 73, 74
 toe-web infection, 71
 of fungal infections
 candidiasis, 177-179, 178
 onychomycosis, 169-171
 pityriasis versicolor, 185-186
 tinea, 153-155, 157-159, 161, 164-165
 of infestations and ectoparasites
 lice, 193, 198-199
 scabies, 203, 204
 of viral infections
 condyloma, 145-146, 146t, 147
 herpes simplex (HSV), 118-119
 molluscum contagiosum (MCV), 137-138, 138
 varicella zoster (VZV), 127-130, 128-129
 variola, 141-143, 142, 142t
Clostridium difficile-associated pseudomembranous colitis, 17t
 Clotrimazole, 74, 180t, 182, 183t
 formulations and dosing, 162t, 180t
 CMV (cytomegalovirus), 117
 Co-trimoxazole, 29
 Coagulase-negative *staphylococci* isolates, 15t, 23t
 Cold sores, 118t
 Coliform bacteria, 51
 Colitis, *Clostridium difficile*-associated, 17t
 Colonization, nasal and skin, 29-31
 Community-acquired MRSA. See *CA-MRSA*.
 Complete blood count, 81
 Complicated skin and skin-structure infections, 77-114
 characteristics of, 77, 78t, 79
 indications of, 14t
 overview, 13, 77-86
 signs and symptoms, 78, 81t
 treatment, 78-105, 82t-85t, 88t-89t

Complicated soft tissue infections, 77, 80, 81
 Compresses, acetic acid, 72
 Compression therapy, 58, 60
 Concentration-dependent antibiotics, 13-16, 15t
 Condyloma, 145, 145-150
 clinical manifestations, 145-146, 146t, 147
 condyloma acuminata, 145
 diagnosis, 146, 146t
 treatment, 147-149, 148t
 Congenital varicella infection, 128-129
 Conjunctivitis, 193
 Corticosteroids, 157, 182
Corynebacterium minutissimum, 69
Corynebacterium spp, 73
 Crab lice. See *Pubic lice*.
 Creatine kinase, 28
 Creatinine bicarbonate, 81
 Creatinine phosphokinase, 81
 Crotamiton, 199, 205, 207t
 CRP, 81
 Cruex (clotrimazole), 162t, 180t
 Crusted scabies, 203. See also *Scabies*.
 Cryoglobulinemia, 67
 Cryotherapy, 149
Cryptococcus, 138
 Cultures, 29, 40-44, 45
 in bacterial infections, 45, 48, 56, 67, 71, 75
 in complicated infections (cSSSIs), 81, 105
 in viral infections, 121
 Cutaneous hemorrhage, 14t, 28, 78, 81t
 Cytomegalovirus (CMV), 117

 D-zone tests, 27-28
 Dakin's solution, 30
 Dalfopristin-quinupristin. See *Quinupristin-dalfopristin*.
 Daptomycin, 15t, 28, 89t, 90-94, 94
 Decubitus ulcers, 58
 Derimine (oxiconazole), 162t, 180t
 Dermatitis, secondarily infected, 41
Dermatophilus congolensis, 73
 Dermatophyte infections, 11, 151, 152, 153. See also *Tinea*.
 Desonex AF (clotrimazole), 162t, 180t

 Diabetes-related issues, 13, 47
 cellulitis, 55, 57, 58
 diabetic foot ulcers/wounds, 14t, 90, 99
 ecthyma, 65
 erythrasma, 69
 MRSA, 25
 Diagnosis
 of bacterial infections
 abscess, 45
 cellulitis, 55-56
 ecthyma and ecthyma gangrenosum, 65, 67
 erysipelas, 59
 folliculitis and hot-tub folliculitis, 47-48
 furuncles/carbuncles, 51
 impetigo, 61
 perianal streptococcal disease, 75
 pitted keratolysis, 73
 toe-web infection, 71
 of fungal infections
 candidiasis, 177-179
 onychomycosis, 169-171
 pityriasis versicolor, 185-186
 tinea, 153-155, 157-159, 161, 165-166
 of infestations and ectoparasites
 lice, 193, 198-199
 scabies, 203
 of viral infections
 condyloma, 146, 146t
 herpes simplex (HSV), 121-122, 122t
 molluscum contagiosum (MCV), 138, 139t, 146t
 varicella zoster (VZV), 130-133, 133t
 variola, 142t, 143
 Diaper dermatitis, 75, 177
 Dicloxacillin, 30, 49, 52, 57, 67, 82t
 Dimethylsulfoxide. See *DMSO*.
 Distal dactylitis, blistering, 14t
 DMSO (dimethylsulfoxide), 155, 159
 Dog bites, 57
 Down syndrome, 203
 Doxycycline, 57, 79, 82t, 84t
 Drainage therapies, 11, 26, 40-43, 49

- EBV (Epstein-Barr virus), 117
- Econazole, 72, 160, 162t, 180t
- Ecostatin (econazole), 162t, 180t
- Ecthyma and ecthyma gangrenosum, 65-68
- ecthyma, 65-67
 - clinical features/diagnosis, 65, 66
 - pathogens, 65
 - treatment, 65-67
 - ecthyma gangrenosum, 67-68
 - clinical features/diagnosis, 67
 - pathogens, 67-68
 - treatment, 68
 - “punched out” ulcers, 65, 66
- Ectoparasites. See *Infestations and ectoparasites*.
- Eczema, 30
- Eczema herpeticum, 118t
- Edema, 173t
- Eikenella corrodens*, 79
- Empiric antibiotic therapies, 29, 39, 40-44
- Empyema, 78
- Enteric bacilli, 15t
- Enterobacteriaceae, 99
- Enterobacter aerogenes*, 103
 - Enterobacter cloacae*, 98
 - Enterococcus faecalis*, 98
- Eosinophilic folliculitis, 47. See also *Folliculitis and hot-tub folliculitis*.
- Epidermis, fungal infections, 151
- Epstein-Barr virus (EBV), 117
- Ertaczo (sertaconazole), 162t, 180t
- Ertapenem, 78, 82t, 84t
- Erysipelas, 59-60
- clinical features/diagnosis, 59, 60
 - pathogens, 59-60
 - treatment, 60
- Erythema, 55, 75, 164, 177-178
- Erythrasma, 69-70
- clinical features/diagnosis, 69, 70
 - pathogens, 69
 - treatment, 69-70
- Erythromycin, 15-16, 22t-24t
- inducible resistance, 28
 - Erythromycin (*continued*)
 - treatment uses, 52, 57, 60, 69-70, 73, 75
 - for MRSA, 25, 27, 30
- Escherichia coli*, 15t, 68, 71, 98, 103
- Exanthema, 193
- Exelderin (sulconazole), 163t
- Famciclovir, 122-123, 124t-125t, 133-135, 134t
- Fever blisters, 118t
- Fingernails. See *Nails*.
- Fluconazole, 155, 156t, 161, 182, 187t, 188
- Fluctuance, 40, 43-44
- (5-)Fluorouracil, 148t
- Fluoroquinolones, 15, 15t, 17t, 87
- indications for, 17t
 - MRSA emergence and, 17t, 29
 - treatment uses, 28, 58, 68, 83t, 85t
- 5-Fluorouracil, 148t
- Folliculitis and hot-tub folliculitis, 47-50.
- See also *Furuncles/Carbuncles*.
 - clinical features/diagnosis, 47-48
 - noninfectious, 47
 - pathogens, 49
 - treatment, 49
- Foot infections. See *Tinea (tinea pedis)*.
- Foot ulcers, diabetic, 14t, 90, 99
- Foscarnet, 125t
- Fournier’s gangrene, 77, 80
- Fungal infections, 151-188
- candidiasis, 177-184
 - dermatophytes, 11, 151, 152
 - duration of treatment, 160-161, 166, 172
 - ecthyma gangrenosum and, 67-68
 - nondermatophytes, 151
 - onychomycosis, 169-175
 - outpatient visits and cost, 151
 - overview, 151-152
 - pityriasis versicolor, 185-188
 - structures affected, 151
 - tinea, 153-168
- Furuncles/carbuncles, 51-53
- clinical features/diagnosis, 51, 52

- Furuncles/carbuncles (*continued*)
 pathogens, 51
 treatment, 52
- Furunculosis, 14t
 recurrent, 52
- Fusarium*, 68
- Fusidic acid, 18t, 22t-24t, 31
- Fusobacterium* spp, 78, 79
- Gabapentin, 135
- Gas-containing abscesses, 14t, 28, 45, 78, 81t
- Gatifloxacin, treatment uses, 83t, 85t
- Genital herpes, 118t, 119, 120
 treatment, 122-123, 124t, 125t
- Genital warts, 145-146, 146t, 147
 treatment, 147-149, 148t
- Gentamicin, 22t-24t, 68, 87
- Gentian violet, 203
- Giant cells, 122, 130-131
- Gingivostomatitis, 119
- Glomerulonephritis, poststreptococcal, 63, 67, 76
- Gonorrhea, 199
- Gram-negative bacteria, 29, 57, 67, 71, 77, 98
 treatment, 16t, 103, 107t
- Granulocyte-macrophage colony-stimulating factor, 68
- Griseofulvin, 155, 156t, 160, 166, 171
- HA-MRSA (health care-associated MRSA), 25, 28.
 See also *MRSA*.
- Habit tic deformity, 169
- Haemophilus influenzae* cellulitis, 55-56
- Haemophilus parainfluenzae*, 103
- Hair
 bacterial infections
 folliculitis, 47-50
 furuncles/carbuncles, 51-53
 fungal infections, 151. See also *Tinea*.
- Head lice, 193-198. See also *Lice*.
- Health care-associated MRSA, 25, 28. See also *MRSA*.
- Hemorrhage, cutaneous, 14t, 28, 78, 81t
- Hepatotoxicity, 172, 173t
- Herpes, 117-126, 118t. See also *Herpes simplex virus (HSV)*.
 genital, 118t, 119, 120
 treatment, 124t, 125t
 herpes febrilis, 118t
 herpes gladiatorum, 118t
 herpes labialis, 118t
 herpes progenitalis, 118t
 herpes simplex (HSV), 117-126. See also *Herpes simplex virus (HSV)*.
 herpes zoster (shingles), 127, 129-130, 130, 132
 herpetic whitlow, 118t
 neonatal, 119, 124t
 orolabial, 119, 119, 124t
 sexual activity and, 117, 118
- Herpes simplex virus (HSV), 117-126
 asymptomatic, 117, 118
 clinical features, 118-119
 diagnosis, 121-122, 122t
 manifestations, 117, 118t
 primary infection, 119
 risk factors for sexual transmission, 118
 sexual activity and, 117, 118
 treatment, 122-123, 124t-125t
 vs HHVs, 117
 vs VZV, 131-133, 133t
- Herpes zoster, 127, 129-130, 130, 132. See also *Varicella zoster*.
 vaccine (Zostavax), 135
- Hidradenitis suppurativa, 45
- HIV (human immunodeficiency virus)
 antiretroviral therapy, 139t, 140
 folliculitis and, 47
 HSV and, 125t
 onychomycosis and, 169
 superficial skin infections and, 14t
 zoster and, 130
- HLA types, 190
- Hospitalization, indications for, 28, 60, 81
- Hot-tub folliculitis, 48. See also *Folliculitis*.
- HPV (human papillomavirus), 145. See also *Condyloma*.
 diagnosis, 146
 vaccine, 149

- HSV. See *Herpes simplex virus (HSV)*.
- Human bites, 28, 79-81, 84t-85t
- Human herpes viruses (HHVs). See *Herpes; Herpes simplex virus (HSV)*.
- Human immunodeficiency virus. See *HIV*.
- Human papillomavirus (HPV), 145
- Hyperhidrosis, 71, 73
- IDSA (Infectious Disease Society of America) guidelines, 28, 81
- Imidazoles, 160, 165-166, 179, 182, 186, 187t
cost of, 166
formulations and dosing, 162t-163t, 180t-181t
resistance to, 179
- Imipenem, 82t, 84t
- Imipenem/cilastin, 96t
- Imiquimod, 116, 139-140, 148t, 149
- Immunocompromised/immunosuppressed patients, 14t
antibiotic therapies in, 55, 60, 65, 67
antifungal therapies in, 179
antiviral therapies in, 115-116, 123, 124t-125t, 133-135, 134t, 139t
molluscum contagiosum (MCV) in, 138, 139t
onychomycosis in, 169
scabies in, 203
varicella zoster in, 127, 130, 132
- Immunotherapies, 139t
- Impetigo, 61-64
Bockhart's, 47
bullous vs nonbullous, 61
clinical features/diagnosis, 61, 62
contagiousness of, 63
pathogens, 62
prevalence, 13, 61
secondary, lice and, 193
treatment, 31-33, 42, 63
- Infections, skin. See *Skin and skin-structure infections*.
- Infectious Disease Society of America (IDSA), 28, 81
- Infestations and ectoparasites, 189-202
basics/overview, 189-191
life cycle statistics, 189-190
risk factors, 190
scope/prevalence, 189
- Infestations and ectoparasites (*continued*)
lice, 193-202
scabies, 203-208
- Inflammatory bowel disease (IBD), 75
- Inguinal adenopathy, 119, 121
- Interferon-alpha, 148t, 149
- Intertrigo, candidal, 177, 178
- Intravenous. See *IV (intravenous)*.
- Iodine tincture, 139
- Itraconazole, 155, 160, 166, 171-172, 182, 187t, 188
cost of, 187t, 188
dosing, 156t, 171t, 187t
side effects, 172, 173t, 187t
- IV (intravenous)
antibiotic therapies, 57, 60, 78
catheters, 67
drug use, 25, 26t
- Ivermectin, 194, 205
- Jock itch (tinea cruris), 161, 162t-163t. See also *Tinea*.
- Keratin, 151
- Keratolysis, pitted. See *Pitted keratolysis*.
- Kerions, 154-155, 154
- Ketoconazole, 155, 160, 187-188, 187t
cautions, liver injury, 187t, 188
formulations and dosing, 162t, 180t
- Ketolides, 15t
- Klebsiella oxytoca*, 103
- Klebsiella pneumoniae*, 98, 103
- Klebsiella* spp, 15t
- KOH (potassium hydroxide), 155, 159, 170, 179, 185
- Kytococcus sedentarius*, 73
- Lactic acid, 139
- Lamisil and Lamisil AT (terbinafine), 163t, 181t
- Langerhans cell histiocytosis, 203
- Lauric acid monoester ointments, 29
- Levofloxacin, 96t
- Lice, 193-202
body lice, 198
clinical features/diagnosis, 198

- Lice, body lice (*continued*)
- life cycle, 189
 - treatment, 198
- clinical features/diagnosis, 193, 198-199
- head lice, 193-198, 194
- clinical features/diagnosis, 193, 194
 - life cycle, 189
 - prevalence, 189
 - school policies, 195-198
 - treatment, 193-198, 196t-197t
 - retreatment, 195
 - life cycles, 189-190
- pubic lice, 198-200, 199
- clinical features/diagnosis, 198-199
 - life cycle, 189-190
 - treatment, 199-200
- resistant lice, 194-195
- treatment, 193-200, 196t-197t
- Lichen planus/lichen striatus, 169
- Lidocaine, 135
- Life cycles, ectoparasites, 189-190
- Lincosamides, 17t, 28
- Lindane, 194, 196t, 199, 205, 206t
- Linezolid, 15t, 87-90, 92-93
- dosing, 15-16, 88t
 - MIC values, 99
 - for MRSA, 28, 87
- Liquid nitrogen, 116, 139
- Liver damage, 172, 173t, 187t, 188
- Loprox (ciclopirox olamine), 163t, 181t
- Lotrimin and Lotrimin AF (clotrimazole), 162t, 180t
- Lupus erythematosus, 172
- Lymphadenopathy, 193
- Lymphangitis, ascending, 55
- Lymphedema, 60
- Maceration, 71
- Macrolides, 15t, 17t, 41-44, 52, 60, 75
- Maculae ceruleae, 198
- Majocchi's granuloma, 158-159
- Malassezia*, 152, 185
- Malathion, 194, 197t, 199
- MCV (molluscum contagiosum virus), 137-140.
- See also *Molluscum contagiosum*.
- Mentax (butenafine), 163t, 181t
- Meropenem, 82t, 84t
- Methicillin-resistant *Staphylococcus aureus*. See MRSA.
- Methicillin-susceptible *Staphylococcus aureus*. See MSSA.
- Metronidazole, 58, 82t, 84t
- MIC (minimum inhibitory concentration), 13, 18, 21t-24t
- oral antibiotics, 21t
 - time-dependent antibiotics, 15-16
 - topical antibiotics, 22t-24t
- Micatin (miconazole), 162t, 180t
- Miconazole, 70, 74, 162t, 180t
- formulations and dosing, 162t, 180t
- Micozole (miconazole), 180t
- Micrococcus sedentarius*, 73
- Minimum inhibitory concentration. See MIC.
- Minocycline, 94
- Moccasinlike tinea pedis, 164-165, 165, 166
- Moist heat therapies, 52
- Molluscum contagiosum, 137-140
- clinical features, 137-138
 - umbilicated papules, 137, 138
 - diagnosis, 138, 139t, 146t
 - MCV (molluscum contagiosum virus), 137
 - treatment, 139-140, 139t
- Monistat (miconazole), 180t
- Monkeypox, 142t
- Mononucleosis-like syndrome, 119
- Moraxella catarrhalis*, 103
- Morganella morganii*, 71, 103
- Moxifloxacin, 83t, 85t
- MRSA (methicillin-resistant *Staphylococcus aureus*), 25-38
- colonization, nasal and skin, 29-31
 - community-acquired (CA-MRSA), 25-38
 - complicated, 78
 - fluoroquinolones and, 17t
 - health care-associated (HA-MRSA), 25, 28
 - prevalence and impact, 11, 25
 - risk factors, 25, 26t
 - treatment, 26-31
 - antibiotic therapies, 25, 26-29, 30, 101

MRSA (methicillin-resistant *Staphylococcus aureus*),
treatment (*continued*)
serious infection, 28
sulfa drugs, 25, 26-27
topical therapies, 29-30, 31-33
MSSA (methicillin-susceptible *Staphylococcus aureus*), 11,
16t, 25
Mucosal candidiasis, 178-179
Mupirocin, 18t, 31, 63, 74
emerging resistance, 29, 31
MIC values, 22t-24t
use in nares, 29
Mycelex (clotrimazole), 162t, 180t
Mycobacteria, 67
Myfungar (oxiconazole), 162t, 180t

Nafcillin, 57, 81, 86
Naftifine, 163t
Naftin (naftifine), 163t
Nails, fungal infections of, 151, 169.
See also *Onychomycosis*.
Narcotics, 135
Nasal colonization, 29-31
Necrosis, 77, 79
Necrotizing fasciitis, 67, 77, 80
Neisseria meningitidis, 68
Neomycin, 22t-24t, 63
Neonatal herpes, 119, 124t
Nerve blocks, 135
Neutropenia, 57, 68
Nickerson's medium, 179
Nizoral and Nizoral AD (ketoconazole), 162t, 180t
Norwegian scabies, 203. See also *Scabies*.
Nose, topical therapies, 29-33
Nystatin, 179, 182, 183t

Oceral (oxiconazole), 162t, 180t
Ofloxacin, 30
Okinazole (oxiconazole), 162t, 180t
Onychomycosis, 169-175
clinical features/diagnosis, 169-171

Onychomycosis (*continued*)
clinical variants, 169-170
distal or lateral subungual, 169, 170
proximal, 169
superficial, 170
treatment, 171-174
confirmation of diagnosis before, 170-171
costs of, 171
systemic agents, 171-172, 171t
topical agents, 172-174
Oral antibiotic therapies, 16t-17t, 21t. See also *Antibiotic therapies*.
Orolabial herpes, 119, 119, 124t
Oxiconazole, 160, 162t, 180t
Oxistat (oxiconazole), 162t, 180t
Oxizole (oxiconazole), 162t, 180t

Pain, disproportionate, 14t, 28, 78
Pap (Papanicolou) smears, 147
Parasites. See *Infestations and ectoparasites*.
Paronychia
acute, 14t, 177-178
treatment, 179-180
chronic, 182
Pasteurella multocida, 57
Pasteurella spp, 78
Pathogens, 15t. See also *specific pathogens*.
in abscess, 45
Actinomyces spp, 73
Aeromonas hydrophila, 57, 68
in animal bites, 78
Aspergillus spp, 68
Candida spp, 177-184
Capnocytophaga canimorsus, 57, 78
in cellulitis, 57
Clostridium difficile, 17t
common, 15t
Corynebacterium minutissimum, 69
Corynebacterium spp, 73
Cryptococcus, 138
Dermatophilus congolensis, 73
in ecthyma and ecthyma gangrenosum, 65, 67

Pathogens (*continued*)

in erysipelas, 59-60
in erythrasma, 69
Escherichia coli, 15t
in folliculitis and hot-tub folliculitis, 49
in furuncles/carbuncles, 51
Haemophilus influenzae, 55-56
in human bites, 79
in impetigo, 62
Klebsiella spp, 15t
Kytococcus sedentarius, 73
Malassezia, 152, 185
Micrococcus sedentarius, 73
Morganella morganii, 71, 103
MRSA, 25-38
MSSA, 11, 16t, 25
Neisseria meningitis, 68
in perianal streptococcal disease, 75
in pitted keratolysis, 73
Pityrosporum, 151, 153, 185
Proteus mirabilis, 71, 103
Pseudomonas aeruginosa, 49
Serratia marcescens, 68
Staphylococcus aureus, 15t, 45, 49
Staphylococcus epidermis, 15t
Streptococcus agalactiae, 15t
Streptococcus pyogenes, 15t
in toe-web infection, 71
unusual, 77
Vibrio, 57, 58, 77
in viral infections, 115, 127
PCR (polymerase chain reaction), 121-122, 138, 146
Pearly penile papules, 146t
Pediculicides, 196t-197t
Pediculosis capitis, 193-198. See also *Lice (head lice)*.
Penciclovir, 124t
Penicillins
activity spectra and characteristics, 16t-17t
allergies to, 57, 79
antipseudomonal, 68
MIC values, 24t
penicillin/ β -lactamase inhibitors, 28, 40-44

Penicillins (*continued*)

penicillin/penicillinase inhibitors, 17t
penicillinase-resistant penicillins, 40-44, 49, 57, 63
semisynthetic, 16t
as time-dependent antibiotics, 15t
treatment uses, 60, 75, 82t, 86
for MRSA, 28
Peptostreptococcus, 79
Perianal streptococcal disease, 75-76
clinical features/diagnosis, 75, 76
pathogens, 75
treatment, 75-76
Perlèche, 178-179, 182
Permethrin, 194, 196t, 199, 205, 206t
Pharmacokinetics, antibiotics, 17-18, 19-20
Pharyngitis-like syndrome, 119
Phenol, 139
PHN. See *Postherpetic neuralgia*.
Photosensitivity, 17t, 172
Phthirus pubis, 199
Pinworm disease, 75
Piperacillin, 68, 82t
Piperacillin/tazobactam, 58, 96t
Pitted keratolysis, 73-74
clinical features/diagnosis, 73, 74
pathogens, 73
treatment, 73-74
Pityriasis versicolor, 185-188
clinical features/diagnosis, 185-186, 186
treatment, 186-188, 187t
Pityrosporum, 151, 152, 185
PK profiles, 17-18, 19-20
Pleuromutilins, 32
Pneumonitis, 78
Podophyllin, 139, 148t, 149
Podophyllotoxin, 139, 148t, 149
Polyenes, topical, 179
Polymerase chain reaction. See *PCR*.
Porphyromonas spp, 78, 79
Postherpetic neuralgia (PHN), 127, 135
Poststreptococcal glomerulonephritis, 63, 67, 76
Potassium hydroxide. See *KOH*.

Pregnancy categories of agents, 196t-197t, 199, 206t
Prevotella, 79

Primary varicella (chickenpox), 127-128, 128-129

Proteus mirabilis, 71, 103

Pruritus, 164, 177, 185, 203

treatments, 205

Pseudomonas aeruginosa, 49, 57, 67, 71

Pseudomonas spp, 77

Psoriasis, 75, 169

Pubic lice, 198-200. See also *Lice*.

Punched out ulcers, 65, 66

Pus-containing infections, 43

Pyoderma gangrenosum, 67

Pyrethrins, 194, 197t, 199

Quinolones, 71

Quinupristin-dalfopristin, 16, 28, 89t, 99-101

Regional adenopathy, 59

Retapamulin, 18t, 22t-24t, 32-33

for MRSA, 32, 33

for nasal carriage, 29-30

Rifampin, 30, 86, 95, 99

Ringworm (tinea corporis), 157-161, 162t-163t.

See also *Tinea*.

Sabouraud's medium, 179

Salicylic acid, 70, 139, 149

Saltwater exposure, 57

Scabies, 203-208

clinical features/diagnosis, 203, 204, 205

prevalence, 189

treatment, 205, 206t-207t

Scalp, fungal infections. See *Tinea*.

Seborrheic dermatitis, 75

Seborrheic scale, 193

Sebum, 185

Secondary infections, 14t

treatment, 31-33, 40-41

Selenium sulfide, 155, 186-188, 187t

Septic arthritis, 78

Serratia marcescens, 68

Sertaconazole, 162t, 180t

Sexually-transmitted diseases (STDs), 190, 199, 200

Shingles (herpes zoster), 127, 129-130, 130, 132

Silver nitrite, 139

Skin and skin-structure infections, 11-13

acute bacterial (ABSSSIs), 103, 105

bacterial, 13-114

complicated (cSSSIs), 13, 14t, 77-114

fungal, 151-188

infestations and ectoparasites, 189-202

pathogens, most common, 15t

prevalence and impact, 11-13

serious, signs of, 28

treatment, general guidelines, 28-29, 40-44

uncomplicated, overview, 13, 14t

viral, 115-150

Skin colonization, 30-31

Sloughing, 14t, 78, 81t

Smallpox, 141-143, 142. See also *Variola*.

SMX (sulfamethoxazole). See *TMP/SMX (trimethoprim/sulfamethoxazole)*.

Soaps, antibacterial, 49, 52, 70

Sodium fusidate ointment, 70

Specialists, consultation with, 29, 40-44, 81, 105

Spectazole (econazole), 162t, 180t

Staphylococci

prevalence and impact, 11

risk factors for carriage, 25

Staphylococcus aureus

MRSA, 25-38, 78

MSSA, 11, 16t, 25

prevalence and impact, 11, 15t

in specific conditions, 45, 49, 51, 57, 60, 62, 65, 68, 75, 79

Staphylococcus epidermis, 15t

STDs (sexually-transmitted diseases), 190, 199, 200

Stevens-Johnson syndrome, 173t

Streptococci

β -hemolytic, 59, 62, 65, 75

poststreptococcal glomerulonephritis, 63, 67, 76

prevalence and impact, 11, 15t

in specific conditions, 51, 79

Streptococcus agalactiae, 15t, 103

Streptococci (*continued*)

- Streptococcus pneumoniae*, 98
- Streptococcus pyogenes*, 57, 59, 65, 98
 - treatment, 16t, 103
- Streptozyme, 59
- Sulconazole, 161, 163t, 181t
- Sulcosyn (sulconazole), 163t, 181t
- Sulfa drugs, 25, 26-27
- Sulfamethoxazole. See *TMP/SMX (trimethoprim/sulfamethoxazole)*.
- Sulfur, precipitated, 205
- Superficial folliculitis, 47
- Surgery, 77, 78
- Sycosis vulgaris, 47
- Syphilis, 142t, 190
- Syphilitic condyloma lata, 146t
- Systemic symptoms, 78, 81
- Systemic toxicity, 81

- Tazobactam. See *Piperacillin/tazobactam*.
- TCAs (tricyclic antidepressants), 135
- Teicoplanin, 99
- Telavancin, 101-103, 102
- Tepid bath therapy, 133
- Terbinafine, 155, 160, 165-166, 171-172, 186, 187t
 - combined with topical agents, 174
 - cost of, 166
 - formulations and dosing, 156t, 163t, 171t, 181t
 - side effects, 172, 173t
- Tetracyclines, 15t, 16, 17t
 - adverse events, 17t
 - MIC values, 22t-24t
 - treatment uses, 25, 27, 40-44, 58
- Thrush, 178-179
 - treatment, 182, 183t
- Thymol, 179
- Tigecycline, 89t, 94-99, 96t
 - MIC values, 99
 - for MRSA, 28, 95-99, 99, 100t
- Time-dependent antibiotics, 13-16, 15t
- Tinea (dermatophyte infections), 152, 153-168
 - clinical features/diagnosis, 153-155, 157-159, 161, 164-165

Tinea (dermatophyte infections) (*continued*)

- tinea capitis, 153-157
 - “black dot,” 154
 - clinical features/diagnosis, 153-155, 154
 - inflammatory, 154-155, 154
 - kerions, 154-155, 154
 - noninflammatory, 153, 154
 - treatment, 155-157, 156t
- tinea corporis, 157-159
 - clinical features/diagnosis, 157-159, 157
 - treatment, 159-161, 162t-163t
- tinea cruris, 161
 - clinical features/diagnosis, 161
 - treatment, 161, 162t-163t
- tinea incognita, 158, 158
- tinea pedis, 164-166
 - clinical features/diagnosis, 164-165, 164
 - moccasinlike, 164-165, 165
 - treatment, 162t-163t, 165-166
- tinea unguium, 169
- tinea versicolor. See *Pityriasis versicolor*.
- toe-web infection and, 71
 - treatment, 155-157, 159-161, 162t-163t, 165-166
- Tinea versicolor. See *Pityriasis versicolor*.
- TMP/SMX (trimethoprim/sulfamethoxazole), 17t, 40-44,
 - 52, 58, 79, 82t, 84t
- Toe-web infection, 71-72
 - clinical features/diagnosis, 71
 - pathogens, 29, 71
 - treatment, 71-72
- Toenails. See *Nails*.
- Tolnaftate, 70, 186
- Topical agents, 31-33. See also *specific agents and conditions*.
 - antibiotic therapies, 18t, 22t-24t, 29-33
 - antifungal agents, 159-160, 162t-163t, 172-174,
 - 180t-181t, 187t
 - antiviral agents, 115-116
- Traumatic lesions
 - secondarily infected, 14t, 40
 - treatment, topical, 31-33, 40

Treatment

- algorithms for, 39, 40-44
- of bacterial infections, 13-24, 15t-18t
 - abscess, 45-46
 - algorithms for, 39, 40-44
 - animal and human bites, 82t-85t
 - cellulitis, 57-58
 - complicated infections, 78-105, 82t-85t
 - ecthyma and ecthyma gangrenosum, 65-67, 68
 - erysipelas, 60
 - erythrasma, 69-70
 - folliculitis and hot-tub folliculitis, 49
 - furuncles/carbuncles, 52
 - impetigo, 42, 63
 - MRSA, 26-33
 - perianal streptococcal disease, 75-76
 - pitted keratolysis, 73-74
 - surgery, 77
 - toe-web infection, 71-72
- of fungal infections
 - candidiasis, 179-182, 180t-181t, 183t
 - duration of treatment, 160-161, 166, 172
 - onychomycosis, 171-174
 - pityriasis versicolor, 186-188, 187t
 - tinea capitis, 155-157, 156t
 - tinea corporis, 159-161, 162t-163t
 - tinea pedis, 162t-163t, 165-166
 - general guidelines, 29, 39, 40-44
- of infestations and ectoparasites
 - lice, 193-198, 196t-197t, 199-200
 - scabies, 205, 206t-207t
- initial empiric, 29, 39, 40-44
- of viral infections
 - condyloma, 147-149, 148t
 - herpes simplex (HSV), 122-123, 124t-125t
 - molluscum contagiosum (MCV), 139-140, 139t
 - varicella zoster (VZV), 133-135, 134t
 - variola, 143
- Tretinoin creams and gels, 139
- Triazoles, 155
- Trichomoniasis, 190
- Trichophyton tonsurans*, 153

- Triclosan-based products, 30
- Tricyclic antidepressants (TCAs), 135
- Trimethoprim/sulfamethoxazole. See *TMP/SMX*.

Uncomplicated skin and skin-structure infections, 13, 14t.

- See also *specific topics*.
- bacterial infections, 13-76
 - treatment algorithms, 39, 40-44
- fungal infections, 151-188
- infestations and ectoparasites, 189-202
- viral infections, 115-150
- Urea 40% cream, 166
- Urinary catheters, 67
- USSSIs. See *Uncomplicated skin and skin-structure infections*.

Vaccines

- HPV, 149
- smallpox (vaccinia), 141
- zoster (Zostavax), 135
- Valacyclovir, 122, 124t-125t, 133-135, 134t
- Vancomycin, 16, 86-87, 88t
 - clinical cure rates, 105, 106t
 - MIC values, 107t
 - treatment uses, 57, 81
 - for MRSA, 28, 86, 101, 102
- Vancomycin derivative. See *Telavancin*.
- Varicella zoster, 127-136. See also *Herpes zoster*.
 - clinical features, 127-130, 128-129
 - congenital varicella, 128-129
 - diagnosis, 130-133, 133t
 - disseminated cutaneous disease, 130, 132
 - in HIV-infected patients, 130
 - primary varicella (chickenpox), 127-128, 128-129, 133t
 - reactivation of, 127, 129, 130, 133t
 - treatment, 133-135, 134t
 - zoster vaccine (Zostavax), 135
 - varicella zoster virus (VZV), 117
 - vs HSV, 131-133, 133t
 - zoster sine herpette, 129
- Variola, 141-143
 - clinical manifestations, 141-143, 142, 142t

Variola (*continued*)
diagnosis, 142t, 143
treatment, 143
variola major/minor, 143
Vibrio spp, 57, 77
Vibrio vulnificus, 57, 58
Violaceous bullae, 14t, 78, 81t
Viral exanthems, 115, 133t
Viral infections, 115-150. See also *specific topics*.
antiviral agents, topical vs systemic, 115-116
condyloma, 145-150
herpes simplex (HSV), 117-126
molluscum contagiosum (MCV), 137-140
overview, 115-116
varicella zoster (VZV), 127-136
variola, 141-143
VZV (varicella zoster virus), 117. See also *Varicella zoster*:
reactivation of, 127, 129, 130, 133t

Warts, anogenital (condyloma acuminata), 145-146, 146t, 147
Water, pathogen exposure and, 57
Western blot technique, 121
Whitfield's ointment, 70
WHO (World Health Organization), 141
Wood's light, 69
World Health Organization (WHO), 141
Wound ulcers, diabetic, 14t

Yeast infections, 72, 152. See also *Candida and candidiasis*.

Zeasorb AF (miconazole), 162t, 180t
Zostavax (zoster vaccine), 135
Zoster. See *Varicella zoster*.
Zoster sine herpete, 129